Research Leader (Toxicology), Cambridge, MA Isomorphic LabsResearch Leader (Toxicology), Cambridge, MACambridge, MAIf you are an experienced, innovative and ambitious scientist looking to play an active part in the AI-driven transformation of the pharmaceutical industry, joining Isomorphic Labs will lift you out of your comfort zone and provide an amazing opportunity for personal growth and development. Since Isomorphic Labs outsource all wet-lab work to external vendors, you will maintain and develop close relationships with the CRO network to: Ensure high quality and timely data generation to support our portfolio projects.
Senior Director, Toxicology Disc Medicine IncSenior Director, Toxicologymassachusetts, MA$261,000–$319,000 / yearReporting directly to the Vice President, Head of Toxicology, the successful candidate will play a pivotal role in leading nonclinical safety assessments and driving toxicology strategy across the Disc portfolio. The ideal candidate will also blend deep technical knowledge in nonclinical safety and pharmacokinetics with strong communication skills to cross-functionally guide programs toward clinical success.
Vice President, Nonclinical Drug Safety & Toxicology Remix Therapeutics IncVice President, Nonclinical Drug Safety & ToxicologyWatertown, MA$293,000–$358,000 / yearThe Non-Clinical Safety and Toxicology leader will partner cross-functionally across therapeutic areas with colleagues in drug discovery, translational, and clinical development functions, ensuring toxicology and nonclinical safety data is shared and communicated transparently and plays a role in informing strategy at all stages of each program's development. Position Summary: Reporting to the Chief Scientific Officer, the Vice President of Nonclinical Drug Safety and Toxicology is a key position within the R&D leadership team and will lead nonclinical aspects of all the company's pipeline programs.
Nonclinical Toxicology Study Monitoring Scientist Vertex Pharmaceuticals IncNonclinical Toxicology Study Monitoring ScientistBoston, MARemote$101,600–$152,400 / yearThis role is best suited for a scientifically grounded, highly organized, collaborative study monitor who thrives in a fast-paced environment, excels at managing multiple studies and competing priorities simultaneously, and communicates clearly and succinctly to drive study execution and decision-making. We are seeking a Nonclinical Toxicology Study Monitoring Scientist to play a critical role in supporting the safety assessment of both large and small molecule modalities including cell and gene therapies across the development pipeline by providing scientific, technical, and operational oversight of outsourced nonclinical studies.
Sr. Scientist- Toxicology StratAcuity Staffing Partners IncSr. Scientist- ToxicologyCambridge, MA$65–$90 / hourIn terms of professional development, Everforth Apex hosts an on-demand training program, provides access to certification prep and a library of technical and leadership courses/books/seminars once you have 6+ months of tenure, and certification discounts and other perks to associations that include CompTIA and IIBA. Our Cambridge based biotech client is looking for a highly motivated Senior Scientist in Toxicology to help shape the preclinical safety strategy for oligonucleotide programs across all stages of development.
Toxicology Research Scientist Vertex PharmaceuticalsToxicology Research ScientistBoston, MassachusettsWork within a close-knit team, this individual will leverage advanced in vitro technologies, laboratory automation, and computational approaches to design, execute, analyze, and derive insights from mechanistic and phenotypic screening assays designed to evaluate the safety of new candidate molecules. We seek talent who bring an external perspective, demonstrate curiosity and sound judgment, and thoughtfully adopt new capabilities that improve decision-making, drive innovation, increase efficiency, and help deliver better outcomes for patients.
Senior Director, Toxicology Amylyx PharmaceuticalsSenior Director, ToxicologyCambridge, MARemote$269,000–$291,667 / yearDevelop and execute comprehensive nonclinical safety strategies to support clinical candidate selection, IND-enabling activities, regulatory submissions, and clinical development across multiple programs including small molecules, peptides, protein-based biologics, anti-sense oligonucleotides. This person will: Serve as a toxicology leader across a diverse and expanding pipeline spanning multiple therapeutic areas and drug modalities, shaping nonclinical safety strategy from discovery to IND-enabling and throughout clinical phases.
Senior Director, Toxicology Amylyx Pharmaceuticals IncSenior Director, ToxicologyCambridge, MARemote$269,000–$291,667 / yearDevelop and execute comprehensive nonclinical safety strategies to support clinical candidate selection, IND-enabling activities, regulatory submissions, and clinical development across multiple programs including small molecules, peptides, protein-based biologics, anti-sense oligonucleotides. This person will: Serve as a toxicology leader across a diverse and expanding pipeline spanning multiple therapeutic areas and drug modalities, shaping nonclinical safety strategy from discovery to IND-enabling and throughout clinical phases.
Research Leader Toxicology, Cambridge, MA Isomorphic Labs LimitedResearch Leader Toxicology, Cambridge, MACambridge, MAIf you are an experienced, innovative and ambitious scientist looking to play an active part in the AI-driven transformation of the pharmaceutical industry, joining Isomorphic Labs will lift you out of your comfort zone and provide an amazing opportunity for personal growth and development. Since Isomorphic Labs outsource all wet-lab work to external vendors, you will maintain and develop close relationships with the CRO network to: Ensure high quality and timely data generation to support our portfolio projects.
Associate Director, Toxicology (Nonclinical Safety Evaluation) City TherapeuticsAssociate Director, Toxicology (Nonclinical Safety Evaluation)Cambridge, Massachusetts$174,000–$196,000 / yearThe Ideal Candidate • PhD or DVM, or equivalent advanced degree in Toxicology, Pharmacology, Pathology, Veterinary Sciences, or a related field, with 5+ years, Masters with 7+ or a Bachelors with 10+ of relevant experience in biotech or pharmaceutical drug development, or direct experience as a Study Director at a GLP-qualified CRO.• Strong experience overseeing outsourced nonclinical safety studies and critically reviewing protocols, data, and final reports.• The Role We’re seeking an Associate Director, Nonclinical Safety Evaluation (NSE) who will play a pivotal role in overseeing and critically evaluating nonclinical safety studies across City’s RNAi therapeutic programs.
Associate Director, Toxicology Parabilis MedicinesAssociate Director, ToxicologyCambridge, MA$170,000–$210,000 / yearParabilis Medicines is seeking a highly motivated and driven Associate Director, Toxicology to lead nonclinical safety programs across a diverse pipeline built on Parabilis' clinically validated Helicon pipeline. The successful candidate will serve as the nonclinical safety lead on cross-functional project teams, working autonomously to define strategy, drive execution, influence candidate selection, and ensure robust safety assessment across our pipeline.
NewAssociate Director, Translational Toxicology, Preclinical Development Wave Life Sciences LtdAssociate Director, Translational Toxicology, Preclinical DevelopmentLexington, MA$170,000–$230,000 / yearOur diversified pipeline is focused on our obesity, alpha-1 antitrypsin deficiency and PNPLA3 I148M liver disease programs and includes clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as several preclinical programs utilizing our versatile RNA medicines platform. Design toxicity studies: coordinate with Preclinical Outsourcing for placement and monitoring of the studies as well as the Bioanalytical and DMPK groups regarding integration of bioanalysis and toxicokinetic aspects into these studies to ensure on-time delivery of key data and study reports.
Vice President, Nonclinical Drug Safety & Toxicology Remix TherapeuticsVice President, Nonclinical Drug Safety & ToxicologyWatertown, MA$293,000–$358,000 / yearThe Non-Clinical Safety and Toxicology leader will partner cross-functionally across therapeutic areas with colleagues in drug discovery, translational, and clinical development functions, ensuring toxicology and nonclinical safety data is shared and communicated transparently and plays a role in informing strategy at all stages of each program’s development. Reporting to the Chief Scientific Officer, the Vice President of Nonclinical Drug Safety and Toxicology is a key position within the R&D leadership team and will lead nonclinical aspects of all the company’s pipeline programs.
Director/Senior Director, Nonclinical Safety (Toxicology) Nimbus TherapeuticsDirector/Senior Director, Nonclinical Safety (Toxicology)Boston, MA$225,000–$285,000 / yearManage nonclinical safety studies conducted by CROs with efficient governance including contract execution, authorization of study amendments, schedule and budget variance management, progress reporting to stakeholders, review of data and draft study reports, completion of contract milestones, study close-out and alignment of nonclinical safety evaluations with drug development efforts and priorities. Collaborate with CMC, Program & Portfolio Management, Clinical, Medical, and Regulatory Affairs to develop program-specific strategies for appropriate data generation in support of development candidate nomination, IND/CTA filing, and clinical development of new small molecule drug entities.
Associate Director / Director, Toxicology Beam TherapeuticsAssociate Director / Director, ToxicologyCambridge, MA$185,000–$260,000 / yearBeam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. Provide toxicology support for regulatory submissions and interactions with health authorities, including the authoring of nonclinical safety sections of US and international regulatory applications, and help resolve nonclinical safety queries.
Associate Director / Director, Toxicology Beam Therapeutics IncAssociate Director / Director, ToxicologyCambridge, MA$185,000–$260,000 / yearBeam's suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. Provide toxicology support for regulatory submissions and interactions with health authorities, including the authoring of nonclinical safety sections of US and international regulatory applications, and help resolve nonclinical safety queries.
Director/Senior Director, Nonclinical Safety Toxicology Nimbus Therapeutics LLCDirector/Senior Director, Nonclinical Safety ToxicologyBoston, MA$225,000–$285,000 / yearManage nonclinical safety studies conducted by CROs with efficient governance including contract execution, authorization of study amendments, schedule and budget variance management, progress reporting to stakeholders, review of data and draft study reports, completion of contract milestones, study close-out and alignment of nonclinical safety evaluations with drug development efforts and priorities. Collaborate with CMC, Program & Portfolio Management, Clinical, Medical, and Regulatory Affairs to develop program-specific strategies for appropriate data generation in support of development candidate nomination, IND/CTA filing, and clinical development of new small molecule drug entities.
NewSenior Scientist, Safety Assessment & Toxicology Data Analytics Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and CompanySenior Scientist, Safety Assessment & Toxicology Data AnalyticsBoston, MA$85,000–$130,000 / yearAdvanced Data Visualization & Analytics: Lead the architectural design and execution of data models that transform raw, multi-dose toxicology data streams, clinical pathology tables, and safety pharmacology metrics into publication-ready visual tools (e.g., exposure-margin heatmaps, benchmark dose plots, and cumulative trend diagnostics) to clearly define therapeutic windows. Cross-Functional Synergy: Act as a senior scientific liaison between Safety Assessment, CMC (for compound inventory tracking), DMPK (for toxicokinetic integration), and Project Management to ensure nonclinical safety deliverables map smoothly to aggressive global project milestones.
NewAssociate Director, Study Operation Manager - Nonclinical Toxicology Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and CompanyAssociate Director, Study Operation Manager - Nonclinical ToxicologyBoston, MA$150,000–$220,000 / yearCentessa Pharmaceuticals is seeking an experienced Associate Director, Study Operations - Nonclinical Toxicology to manage and oversee day-to-day operations for toxicology and safety pharmacology studies conducted in the selected CROs to include study forecasting, budgeting, planning, data management, quality assurance, compliance, communications and collaboration with different functional teams across the portfolio of Orexin agonist programs. Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders.
Associate Director, Program Toxicologist, Translational Medicine and Nonclinical Development BlueRock Therapeutics LPAssociate Director, Program Toxicologist, Translational Medicine and Nonclinical DevelopmentMassachusettsBlueRock Therapeutics, a wholly-owned and independently operated subsidiary of Bayer AG, is a leading engineered cell therapy company using its unique CELL+GENE platform to direct cellular differentiation and genetically engineer cells to create a new generation of cellular medicines that address large patient populations suffering from neurological, cardiovascular, and immunology diseases. Founded in 2016 to capitalize on these technological breakthroughs, we are advancing our novel CELL+GENE platform to develop, manufacture, and deliver an entirely new generation of authentic and engineered cell therapies across three therapeutic areas: neurology, cardiology, and immunology.